查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1439927

核子医学/放射性药物 - 全球市场考量、竞争格局、市场预测（2030）

Nuclear Medicine/Radiopharmaceuticals - Market Insights, Competitive Landscape, and Market Forecast - 2030
出版日期: | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

2022年全球核医/放射性药物市场规模将达到72.0362亿美元，到2030年将达到124.95亿美元，2024-2030年预测期内复合年增长率为9.67%，预计将持续增长。 由于日常生活不活跃导致癌症、心血管疾病和其他慢性疾病的盛行率不断增加，该市场呈现出显着的市场成长。 此外，易患慢性病的老年人口不断增加、全球对影像引导手术和诊断的需求不断增加以及管道中产品的强大存在将在预测期内推动对核医学的需求。 此外，旨在改善核医取得机会的积极政府措施、研究联盟和伙伴关係也推动了核医市场的发展。 同样，研究和开发活动的增加、核医学批准的激增和放射性药物诊断设备的推出、市场中主要参与者的存在等因素创造了市场对核医学/放射性药物的需求。 因此，预计在 2024 年至 2030 年的预测期内，市场将以显着的复合年增长率成长。

核医/放射性药物市场动态

核医/放射性药物市场的关键驱动因素之一是，由于遗传、老化、肥胖和不健康生活方式等多种因素，全球范围内癌症和心血管疾病等疾病的盛行率不断增加。

例如，根据 Globocan 2022 的数据，2020 年全球新增癌症患者为 1,930 万，预计到 2040 年将增加至 3,020 万。 对核子医学的需求正在增加，因为它用于放射治疗等癌症治疗。 核子医学也用于诊断许多神经内分泌肿瘤、前列腺癌和其他肿瘤性恶性肿瘤。

此外，根据世界卫生组织 (WHO) (2022) 的数据，2019 年全球估计有 1,790 万人死于心血管疾病 (CVD)。 单光子发射断层扫瞄 (SPECT) 已应用于心臟病学，以提供有关心臟的代谢和功能资讯。 因此，在适当的时间使用核子医学进行适当的诊断可以降低CVD引起的死亡率。

此外，在世界各地开设核子医学中心提供核子医学治疗也有望进一步推动核医市场的发展。 例如，2022年5月，马来西亚槟城州的槟安医院（PAH）在马来西亚北部开设了一家全面的私人核子医学中心。 该新设施为特定病症和疾病提供诊断和治疗，包括甲状腺功能亢进、甲状腺癌、淋巴瘤和各种癌症引起的骨痛。

此外，与疾病诊断和治疗相关的技术不断进步，以及为满足患者治疗需求而越来越多地批准基于核医学的新型设备，将在未来几年推动市场发展。 例如，2022 年 9 月，GE 医疗宣布推出一款新型核医扫瞄仪，具有新的自动化工作流程功能，可提供对心臟解剖和病理学的深入瞭解，并帮助医生为患者决定正确的治疗方法。

因此，上述因素将共同推动 2024-2030 年预测期内的整体核医/放射性药物市场。

然而，核医设备及其程序的高成本以及严格的监管审批程序可能会对核医/放射性药物市场的成长构成挑战。

核医/放射性药物市场在 COVID-19 大流行期间受到负面影响。 这是因为由于大流行的爆发，门诊就诊被取消，非紧急住院治疗和诊断程序也被停止。 结果，常规实验室测试和诊断减少了。 然而，随着COVID-19疫苗的研发、封锁规定的放鬆以及经济情势的正常化，门诊诊疗等正常医疗服务已恢復，核子医学/放射性药品市场不断增加。市场已步入正轨。

本报告研究和分析了全球核医/放射性药物市场，提供市场规模和预测、驱动因素和挑战、公司和产品概况等。

目录

第一章核医/放射性药物市场报告简介

第 2 章核医/放射性药物市场执行摘要

  • 调查范围
  • 市场概览
  • 竞争评估

第三章监理分析

  • 美国
  • 欧洲
  • 日本
  • 中国

第四章核医/放射性药物市场主要因素分析

  • 核子医学/放射性药物市场驱动因素
  • 核医/放射性药物市场的限制与挑战
  • 核子医学/放射性药物市场机会

第五章核医/放射性药物市场波特五力分析

第六章COVID-19对核医/放射性药物市场的影响分析

第七章核医/放射性药物市场布局

  • 产品类型
    • 诊断产品
    • 治疗产品
  • 依用途
    • 心
    • 紧张
    • 肿瘤
    • 其他
  • 按最终用户
    • 医院
    • 诊断中心
  • 地区
    • 北美
    • 欧洲
    • 亚太地区
    • 其他领域

第8章核医/放射性药物市场的公司与产品概况

  • Lantheus.
  • Cardinal Health.
  • GE Healthcare
  • Curium Pharma
  • Nihon Medi-Physics Co., Ltd.
  • Novartis (Advanced Accelerator Applications)
  • Cambridge Isotope Laboratories, Inc
  • Sotera Health LLC
  • Bracco Imaging SpA
  • Jubilant Pharma Limited
  • Necsa
  • IBA Radiopharma Solutions
  • Bayer AG
  • Norgine
  • EczacIbasI-Monrol
  • NorthStar Medical Radioisotopes, LLC.
  • Eckert & Ziegler.
  • Telix Pharmaceuticals Limited
  • ITM Isotope Technologies Munich SE
  • Mallinckrodt PLC

第9章KOL浏览量

第 10 章专案方法

第 11 章关于 DelveInsight

第 12 章免责声明与联络我们

Product Code: DIMDCL0608

Nuclear Medicine/Radiopharmaceuticals Market By Product Type (Diagnostic Products [Single Photon Emission Computed Tomography (SPECT) {Technetium-99m, Iodine-123, Xenon-133, And Others}, And Positron Emission Tomography (Pet) {Flourine-18, Carbon-11, Gallium-68, And Others}], Therapeutic Products [Alpha Emitters {Astatine-211, Actinium-225, Lead-212, And Others}, Beta Emitters {Lutetium-177, Iodine-131, Yttrium-90, And Others}, And Brachytherapy]), By Application (Cardiology, Neurology, Oncology, And Others), By End-User (Hospitals, Diagnostic Centers, And Others), and by geography is expected to advance at a respectable CAGR forecast till 2030 owing to the increasing burden of chornic diseases such as cardiovascular, cancers, and others and the increasing research & developmental activites concerning to the radiopharmaceuticals across the globe

The global nuclear medicine/radiopharmaceuticals market was valued at USD 7,203.62 million in 2022 and is estimated to grow at a CAGR of 9.67% during the forecast period from 2024 to 2030 to reach USD 12,495 million by 2030. The nuclear medicine/radiopharmaceuticals market is observing a substantial market growth due to the growing prevalence of cancer, cardiovascular, and other chronic diseases owing to the inactive routine. Further, the increasing number of geriatric population prone to chronic diseases, increasing demand for image guided procedures and diagnostics across the world, and presence of a robust products in pipeline will propel the demand of nuclear medicine during the forecast period. Additionally, favorable government initiatives to improve access to nuclear medicine and research collaborations and partnerships will also aid in driving the market of nuclear medicine. Likewise, the increasing research & developmental activities along with the surging nuclear medicine approvals and radiopharmaceutical diagnosis device launches, presence of key players in the market, and other factors will create a requisite for the nuclear medicine/radiopharmaceuticals in the market. Therefore, the market for nuclear medicine/radiopharmaceuticals is estimated to grow at a substantial CAGR during the forecast period from 2024 to 2030.

Nuclear Medicine/Radiopharmaceuticals Market Dynamics:

One of the key aspect for driving the nuclear medicine/radiopharmaceuticals market is the increasing prevalence of cancer, cardiovascular diseases, among others, across the world, owing to various factors such as genetics, age, obesity, and unhealthy lifestyles.

For instance, according to Globocan 2022, there were 19.3 million new cancer cases worldwide in 2020, with the number expected to rise to 30.2 million cases by 2040. The nuclear medicines are used in cancer treatment, such as radiotherapy, leading to an increased demand for nuclear medicine. Also, the nuclear medicine can even be used in the diagnosis of many neuroendocrine tumors, prostate cancer, and other oncologic malignancies.

Moreover, as per the World Health Organization (WHO) 2022, an estimated 17.9 million people died from cardiovascular disorders (CVDs), in 2019, globally. The single photon emission computerized tomography (SPECT) finds applications in cardiology, which provides metabolic and functional information about the heart. Thus, the mortality rate from CVD can be reduced by doing proper diagnosis using nuclear medicine at an apt time.

Additionally, the launch of nuclear medicine centers providing accessibility to nuclear medicine treatments across the world is further expected to boost the market of nuclear medicine. For instance, in May 2022, Penang Adventist Hospital (PAH), located in Pulau Pinang, Malaysia, launched a full-fledged private nuclear medicine center in northern Malaysia. The new facility offers diagnostic and treatment procedures for specific conditions and diseases such as hyperthyroidism, thyroid cancer, lymphomas, and bone pain caused by different types of cancer.

Further, the increasing technological advancements pertaining to the diagnosis and treatment of diseases, and rising approval of new nuclear medicine based devices aid in addressing patients treatment needs will drive the market in the forthcoming years. For instance, in September 2022, GE Healthcare announced the launch of a novel nuclear medicine scanner with a new automated workflow feature that offers an exceptional view of cardiac anatomy and pathology to help physicians to decide the right treatment for a patient.

Therefore, the factors stated above collectively will drive the overall nuclear medicine or radiopharmaceuticals market throughout the forecast period from 2024-2030.

However high cost of nuclear medicine and equipment involved in the procedure, the stringent regulatory approval process, and others may prove to be challenging factors for nuclear medicine/radiopharmaceuticals market growth.

The nuclear medicine/radiopharmaceuticals market was negatively impacted during the period of COVID- 19 pandemic as the outbreak of the pandemic led to the cancellation of outpatient visits and the suspension of non-emergency hospitalization and diagnostic procedures. This resulted in the reduced number of routine clinical examinations and diagnosis procedures. However, vaccine development of COVID-19 has initiated the process of economic recovery with the easing of lockdown restrictions and the return of normalcy in the economic landscape which has initiated the process of resumption of regular healthcare services such as outpatients visits for diagnosis and treatment purpose, thereby bringing the demand for products on track in the nuclear medicine or radiopharmaceuticals market.

Nuclear Medicine/Radiopharmaceuticals Market Segment Analysis:

Nuclear Medicine/Radiopharmaceuticals Market by Product Type (Diagnostic Products [Single Photon Emission Computed Tomography (SPECT) {Technetium-99m, Iodine-123, Xenon-133, and Others}, and Positron Emission Tomography (PET) {Flourine-18, Carbon-11, Gallium-68, and Others}], Therapeutic Products [Alpha Emitters {Astatine-211, Actinium-225, Lead-212, and Others}, Beta Emitters {Lutetium-177, Iodine-131, Yttrium-90, and Others}, and Brachytherapy]), Application (Cardiology, Neurology, Oncology, And Others), End-User (Hospitals, Diagnostic Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the product type segment of the nuclear medicine or radiopharmaceuticals market, the Iodine-125 segment is expected to have a significant revenue share in the year 2023. This is due to the various advantages and applications that are associated with the segment.

Iodine-125 seed implantation can be used in radiation therapy as brachytherapy to treat a number of types of tumors, including prostate cancer, uveal melanomas, brain tumors, rectal carcinoma, advanced pancreatic cancer, and non-small cell lung cancer.

Additionally, the Iodine-125 can also be used in the treatment of gastric cancer, colorectal cancer, liver cancer, gynecological tumor, urinary, nervous system tumor, and others.

Moreover, the Iodine-125 can be used in scanning/imaging of the thyroid. Also, the 125I is useful for glomerular filtration rate (GFR) testing in the diagnosis or monitoring of patients with kidney disease.

Further, in May 2022, a unique collaboration in the field of nuclear medicine has been set up between the Nuclear Research & consultancy Group (NRG) and McMaster University to advance customer service to a new level. Together, they will provide the world with the highest quality radioiodine (iodine-125), used for the treatment of prostate and other various types of cancers, at the highest level of reliability.

Therefore, owing to the above-mentioned factors, the demand of the Iodine-125 upsurges, thereby the category is expected to witness a considerable growth eventually contributing to the overall growth of the global nuclear medicine or radiopharmaceuticals market during the forecast period.

North America is expected to dominate the overall Nuclear Medicine/Radiopharmaceuticals Market:

Among all the regions, North America is expected to dominate the global nuclear medicine or radiopharmaceuticals market in the year 2023 and is expected to do the same during the forecast period from 2024-2030.

This can be ascribed to the growing incidence of cancer, cardiovascular disorders, and others in the region due to the high consumption of processed food and lifestyle changes. Further, the presence of key domicile players in the region, rising burden of geriatric population prone to chronic diseases, favorable reimbursement scenario for radiopharmaceuticals in the United States, and others are among the key factors that contribute to the growth of the nuclear medicine/radiopharmaceuticals market in North America during the forecast period from 2022 - 2028.

For instance, as per the Cancer Facts & Figures 2022, it was estimated in 2022, there will be an estimated 1.9 million new cancer cases diagnosed and 609,360 cancer deaths, in the United States. Thus, the increasing incidence of cancers will surge the demand of nuclear medicines as they are used in the treatment of cancers.

Furthermore, several key players in the United States are taking initiatives to develop new technologies and improve radioisotope options. For example, Eckert & Ziegler Radio pharma GmbH successfully submitted an amendment to their Drug Master File (DMF) for GalliaPharm to the US Food and Drug Administration in September 2022. Gallium-68 from GalliaPharm is used to make diagnostic imaging drugs for Positron Emission Tomography (PET). With the development of higher Ge-68 activity generators and the revision of our DMF, there will be an increase in demand for Ga-68-based diagnostics in the United States.

Also, in October 2022, the U.S. FDA issued a Study May Proceed letter to Curium to begin its Phase-III trial with lutetium Lu 177 PSMA I&T, its investigational product. It is a therapeutic radiopharmaceutical that binds to the Prostate-Specific Membrane Antigen (PSMA) protein.

Therefore, the interplay of the aforementioned factors above would provide a conducive growth environment for the North American region in the nuclear medicine or radiopharmaceuticals market.

Nuclear Medicine/Radiopharmaceuticals Market Key Players:

Some of the key market players operating in the nuclear medicine/radiopharmaceuticals market includes Lantheus., Cardinal Health., GE Healthcare, Curium Pharma, Nihon Medi-Physics Co., Ltd., Novartis (Advanced Accelerator Applications), Cambridge Isotope Laboratories, Inc, Sotera Health LLC, Bracco Imaging SpA, Jubilant Pharma Limited, Necsa, IBA Radiopharma Solutions, Bayer AG, Norgine, EczacIbasI-Monrol, NorthStar Medical Radioisotopes, LLC., Eckert & Ziegler., Telix Pharmaceuticals Limited, ITM Isotope Technologies Munich SE, Mallinckrodt PLC, and others.

Recent Developmental Activities in the Nuclear Medicine:

In March 2022, Bracco Imaging launched Blue Earth Therapeutics to advance the development of therapeutic radiopharmaceutical technology. Blue Earth Therapeutics is building a pipeline of precision-targeted therapeutic radiopharmaceuticals, initially focused on prostate cancer, with plans to expand into additional disease areas in oncology.

In February 2022, Applied Molecular Therapies launched 177Lu PSMATherapy, a molecularly targeted radiopharmaceutical, for treating prostate cancer.

In February 2022, Cerveau Technologies, Inc. and Nihon Medi-Physics announced that they signed a manufacturing service agreement, in which Cerveau grants NMP the right to manufacture [18F] MK-6240, a next generation investigational Positron Emission Tomography (PET) imaging agent.

Key Takeaways from the nuclear medicine/radiopharmaceuticals Market Report Study

  • Market size analysis for current nuclear medicine/radiopharmaceuticals market size (2023), and market forecast for 5 years (2024-2030)
  • The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the nuclear medicine/radiopharmaceuticals market.
  • Top key products/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years
  • Key companies dominating the global nuclear medicine/radiopharmaceuticals market.
  • Various opportunities available for the other competitor in the nuclear medicine/radiopharmaceuticals market space.
  • What are the top performing segments in 2023? How these segments will perform in 2030.
  • Which is the top-performing regions and countries in the current nuclear medicine/radiopharmaceuticals market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for nuclear medicine/radiopharmaceuticals market growth in the coming future?

Target Audience who can be benefited from this Nuclear Medicine/Radiopharmaceuticals Market Report Study

  • Nuclear medicine/radiopharmaceuticals providers
  • Research organizations and consulting companies
  • Nuclear medicine/radiopharmaceuticals-related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and Traders dealing in nuclear medicine/radiopharmaceuticals
  • Various end users who want to know more about the nuclear medicine/radiopharmaceuticals market and latest technological developments in the nuclear medicine/radiopharmaceuticals market.

Frequently Asked Questions for the Nuclear Medicine/Radiopharmaceuticals Market:

1. What are nuclear medicine/radiopharmaceuticals market?

The nuclear medicine is a subfield of molecular imaging that involves the use of radioactive materials or the radiopharmaceuticals to either diagnose or treat the disease. In nuclear medicine imaging, radioisotopes are detected by special cameras attached to a computer, which produces very precise images of the area of the body being examined.

2. What is the global market for nuclear medicine/radiopharmaceuticals market?

The global nuclear medicine/radiopharmaceuticals market was valued at USD 7,203.62 million in 2022 and is estimated to grow at a CAGR of 9.67% during the forecast period from 2024 to 2030 to reach USD 12,495 million by 2030.

3. What are the drivers for the global nuclear medicine/radiopharmaceuticals market?

The nuclear medicine/radiopharmaceuticals market is witnessing a positive market growth owing to the factors such as the rising prevalence of cancer, cardiovascular, and other chronic diseases owing to the sedentary and unhealthy lifestyle. Further, the increasing number of geriatric population prone to chronic diseases, increasing demand for image guided procedures and diagnostics, surging product launches and approvals, presence of key players in the market, and others will create an exigency for the nuclear medicine/radiopharmaceuticals market.

4. Who are the key players operating in the global nuclear medicine/radiopharmaceuticals market?

Some of the key market players operating in the nuclear medicine/radiopharmaceuticals market includes Lantheus., Cardinal Health., GE Healthcare, Curium Pharma, Nihon Medi-Physics Co., Ltd., Novartis (Advanced Accelerator Applications), Cambridge Isotope Laboratories, Inc, Sotera Health LLC, Bracco Imaging SpA, Jubilant Pharma Limited, Necsa, IBA Radiopharma Solutions, Bayer AG, Norgine, EczacIbasI-Monrol, NorthStar Medical Radioisotopes, LLC., Eckert & Ziegler., Telix Pharmaceuticals Limited, ITM Isotope Technologies Munich SE, Mallinckrodt PLC, and others.

5. Which region has the highest share for the nuclear medicine/radiopharmaceuticals market?

Among all the regions, North America is estimated to hold a significant revenue share in the global nuclear medicine/radiopharmaceuticals market. This can be ascribed to the growing incidence of cancer, cardiovascular disorders, and others due to the high consumption of processed food and lifestyle changes, rising geriatric population base in the region, and the presence of key domicile players in the region are the reasons which acts as a supportive factor for the North America nuclear medicine/radiopharmaceuticals market growth.

Table of Contents

1.Nuclear Medicine/Radiopharmaceuticals Market Report Introduction

2.Nuclear Medicine/Radiopharmaceuticals Market Executive Summary

  • 2.1. Scope of the Study
  • 2.2. Market at Glance
  • 2.3. Competitive Assessment

3. Regulatory Analysis

  • 3.1. The United States
  • 3.2. Europe
  • 3.3. Japan
  • 3.4. China

4. Nuclear Medicine/Radiopharmaceuticals Market Key Factors Analysis

  • 4.1. Nuclear Medicine/Radiopharmaceuticals Market Drivers
    • 4.1.1. Rising prevalence of cancer, cardiovascular, and other chronic diseases
    • 4.1.2. Increasing number of geriatric population prone to chronic diseases
    • 4.1.3. Increasing demand for image guided procedures and diagnostics
  • 4.2. Nuclear Medicine/Radiopharmaceuticals Market Restraints and Challenges
    • 4.2.1. High cost of nuclear medicine and equipment involved in the procedure
    • 4.2.2. Stringent regulatory guidelines
  • 4.3. Nuclear Medicine/Radiopharmaceuticals Market Opportunities
    • 4.3.1. Rising research and development opportunities and presence of robust products in pipeline
    • 4.3.2. Surging government initiatives to improve access to nuclear medicine

5. Nuclear Medicine/Radiopharmaceuticals Market Porter's Five Forces Analysis

  • 5.1. Bargaining Power of Suppliers
  • 5.2. Bargaining Power of Consumers
  • 5.3. Threat of New Entrants
  • 5.4. Threat of Substitutes
  • 5.5. Competitive Rivalry

6. COVID-19 Impact Analysis on Nuclear Medicine/Radiopharmaceuticals Market

7. Nuclear Medicine/Radiopharmaceuticals Market Layout

  • 7.1. By Product Type
    • 7.1.1. Diagnostic Products
      • 7.1.1.1. Single Photon Emission Computed Tomography (SPECT)
      • 7.1.1.1.1. Technetium-99m
      • 7.1.1.1.2. Iodine-123
      • 7.1.1.1.3. Xenon-133
      • 7.1.1.1.4. Others
      • 7.1.1.2. Positron Emission Tomography (PET)
      • 7.1.1.2.1. Flourine-18
      • 7.1.1.2.2. Carbon-11
      • 7.1.1.2.3. Gallium-68
      • 7.1.1.2.4. Others
    • 7.1.2. Therapeutic Products
      • 7.1.2.1. Alpha Emitters
      • 7.1.2.1.1. Astatine-211
      • 7.1.2.1.2. Actinium-225
      • 7.1.2.1.3. Lead-212
      • 7.1.2.1.4. Others
      • 7.1.2.2. Beta Emitters
      • 7.1.2.2.1. Lutetium-177
      • 7.1.2.2.2. Iodine-131
      • 7.1.2.2.3. Yttrium-90
      • 7.1.2.2.4. Others
      • 7.1.2.3. Brachytherapy
  • 7.2. By Application
    • 7.2.1 Cardiology
    • 7.2.2. Neurology
    • 7.2.3. Oncology
    • 7.2.4. Others
  • 7.3. By End-User
    • 7.3.1. Hospitals
    • 7.3.2. Diagnostic Centers
    • 7.3.3. Others
  • 7.4. By Geography
    • 7.4.1. North America
      • 7.4.1.1. United States Nuclear Medicine/Radiopharmaceuticals Market in USD million (2021-2030)
      • 7.4.1.2. Canada Nuclear Medicine/Radiopharmaceuticals Market in USD million (2021-2030)
      • 7.4.1.3. Mexico Nuclear Medicine/Radiopharmaceuticals Market in USD million (2021-2030)
    • 7.4.2. Europe
      • 7.4.2.1. France Nuclear Medicine/Radiopharmaceuticals Market in USD million (2021-2030)
      • 7.4.2.2. Germany Nuclear Medicine/Radiopharmaceuticals Market in USD million (2021-2030)
      • 7.4.2.3. United Kingdom Nuclear Medicine/Radiopharmaceuticals Market in USD million (2021-2030)
      • 7.4.2.4. Italy Nuclear Medicine/Radiopharmaceuticals Market in USD million (2021-2030)
      • 7.4.2.5. Spain Nuclear Medicine/Radiopharmaceuticals Market in USD million (2021-2030)
      • 7.4.2.6. Rest of Europe Nuclear Medicine/Radiopharmaceuticals Market in USD million (2021-2030)
    • 7.4.3. Asia-Pacific
      • 7.4.3.1. China Nuclear Medicine/Radiopharmaceuticals Market in USD million (2021-2030)
      • 7.4.3.2. Japan Nuclear Medicine/Radiopharmaceuticals Market in USD million (2021-2030)
      • 7.4.3.3. India Nuclear Medicine/Radiopharmaceuticals Market in USD million (2021-2030)
      • 7.4.3.4. Australia Nuclear Medicine/Radiopharmaceuticals Market in USD million (2021-2030)
      • 7.4.3.5. South Korea Nuclear Medicine/Radiopharmaceuticals Market in USD million (2021-2030)
      • 7.4.3.6. Rest of Asia Pacific Nuclear Medicine/Radiopharmaceuticals Market in USD million (2021-2030)
    • 7.4.4. Rest of the World (RoW)
      • 7.4.4.1. Middle East Nuclear Medicine/Radiopharmaceuticals Market in USD million (2021-2030)
      • 7.4.4.2. Africa Nuclear Medicine/Radiopharmaceuticals Market in USD million (2021-2030)
      • 7.4.4.3. South America Nuclear Medicine/Radiopharmaceuticals Market in USD million (2021-2030)

8. Nuclear Medicine/Radiopharmaceuticals Market Company and Product Profiles

  • 8.1. Lantheus.
    • 8.1.1. Company Overview
    • 8.1.2. Company Snapshot
    • 8.1.3. Financial Overview
    • 8.1.4. Product Listing
    • 8.1.5. Entropy
  • 8.2. Cardinal Health.
    • 8.2.1. Company Overview
    • 8.2.2. Company Snapshot
    • 8.2.3. Financial Overview
    • 8.2.4. Product Listing
    • 8.2.5. Entropy
  • 8.3. GE Healthcare
    • 8.3.1. Company Overview
    • 8.3.2. Company Snapshot
    • 8.3.3. Financial Overview
    • 8.3.4. Product Listing
    • 8.3.5. Entropy
  • 8.4. Curium Pharma
    • 8.4.1. Company Overview
    • 8.4.2. Company Snapshot
    • 8.4.3. Financial Overview
    • 8.4.4. Product Listing
    • 8.4.5. Entropy
  • 8.5. Nihon Medi-Physics Co., Ltd.
    • 8.5.1. Company Overview
    • 8.5.2. Company Snapshot
    • 8.5.3. Financial Overview
    • 8.5.4. Product Listing
    • 8.5.5. Entropy
  • 8.6. Novartis (Advanced Accelerator Applications)
    • 8.6.1. Company Overview
    • 8.6.2. Company Snapshot
    • 8.6.3. Financial Overview
    • 8.6.4. Product Listing
    • 8.6.5. Entropy
  • 8.7. Cambridge Isotope Laboratories, Inc
    • 8.7.1. Company Overview
    • 8.7.2. Company Snapshot
    • 8.7.3. Financial Overview
    • 8.7.4. Product Listing
    • 8.7.5. Entropy
  • 8.8. Sotera Health LLC
    • 8.8.1. Company Overview
    • 8.8.2. Company Snapshot
    • 8.8.3. Financial Overview
    • 8.8.4. Product Listing
    • 8.8.5. Entropy
  • 8.9. Bracco Imaging SpA
    • 8.9.1. Company Overview
    • 8.9.2. Company Snapshot
    • 8.9.3. Financial Overview
    • 8.9.4. Product Listing
    • 8.9.5. Entropy
  • 8.10. Jubilant Pharma Limited
    • 8.10.1. Company Overview
    • 8.10.2. Company Snapshot
    • 8.10.3. Financial Overview
    • 8.10.4. Product Listing
    • 8.10.5. Entropy
  • 8.11. Necsa
    • 8.11.1. Company Overview
    • 8.11.2. Company Snapshot
    • 8.11.3. Financial Overview
    • 8.11.4. Product Listing
    • 8.11.5. Entropy
  • 8.12. IBA Radiopharma Solutions
    • 8.12.1. Company Overview
    • 8.12.2. Company Snapshot
    • 8.12.3. Financial Overview
    • 8.12.4. Product Listing
    • 8.12.5. Entropy
  • 8.13. Bayer AG
    • 8.13.1. Company Overview
    • 8.13.2. Company Snapshot
    • 8.13.3. Financial Overview
    • 8.13.4. Product Listing
    • 8.13.5. Entropy
  • 8.14. Norgine
    • 8.14.1. Company Overview
    • 8.14.2. Company Snapshot
    • 8.14.3. Financial Overview
    • 8.14.4. Product Listing
    • 8.14.5. Entropy
  • 8.15. EczacIbasI-Monrol
    • 8.15.1. Company Overview
    • 8.15.2. Company Snapshot
    • 8.15.3. Financial Overview
    • 8.15.4. Product Listing
    • 8.15.5. Entropy
  • 8.16. NorthStar Medical Radioisotopes, LLC.
    • 8.16.1. Company Overview
    • 8.16.2. Company Snapshot
    • 8.16.3. Financial Overview
    • 8.16.4. Product Listing
    • 8.16.5. Entropy
  • 8.17. Eckert & Ziegler.
    • 8.17.1. Company Overview
    • 8.17.2. Company Snapshot
    • 8.17.3. Financial Overview
    • 8.17.4. Product Listing
    • 8.17.5. Entropy
  • 8.18. Telix Pharmaceuticals Limited
    • 8.18.1. Company Overview
    • 8.18.2. Company Snapshot
    • 8.18.3. Financial Overview
    • 8.18.4. Product Listing
    • 8.18.5. Entropy
  • 8.19. ITM Isotope Technologies Munich SE
    • 8.19.1. Company Overview
    • 8.19.2. Company Snapshot
    • 8.19.3. Financial Overview
    • 8.19.4. Product Listing
    • 8.19.5. Entropy
  • 8.20. Mallinckrodt PLC
    • 8.20.1. Company Overview
    • 8.20.2. Company Snapshot
    • 8.20.3. Financial Overview
    • 8.20.4. Product Listing
    • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: COVID-19 Impact Analysis on Nuclear Medicine/Radiopharmaceuticals Market
  • Table 3: Nuclear Medicine/Radiopharmaceuticals Market Analysis in Global (2021-2030)
  • Table 4: Nuclear Medicine/Radiopharmaceuticals Market Analysis in Global by Product Type (2021-2030)
  • Table 5: Nuclear Medicine/Radiopharmaceuticals Market Analysis in Global by Application (2021-2030)
  • Table 6: Nuclear Medicine/Radiopharmaceuticals Market Analysis in Global by End-User (2021-2030)
  • Table 7: Nuclear Medicine/Radiopharmaceuticals Market Analysis in Global by Geography (2021-2030)
  • Table 8: Nuclear Medicine/Radiopharmaceuticals Market Analysis in North America (2021-2030)
  • Table 9: Nuclear Medicine/Radiopharmaceuticals Market Analysis in North America by Country (2021-2030)
  • Table 10: Nuclear Medicine/Radiopharmaceuticals Market Analysis in the US (2021-2030)
  • Table 11: Nuclear Medicine/Radiopharmaceuticals Market Analysis in Canada (2021-2030)
  • Table 12: Nuclear Medicine/Radiopharmaceuticals Market Analysis in Mexico (2021-2030)
  • Table 13: Nuclear Medicine/Radiopharmaceuticals Market Analysis in Europe (2021-2030)
  • Table 14: Nuclear Medicine/Radiopharmaceuticals Market Analysis in Europe by Country (2021-2030)
  • Table 15: Nuclear Medicine/Radiopharmaceuticals Market Analysis in France (2021-2030)
  • Table 16: Nuclear Medicine/Radiopharmaceuticals Market Analysis in Germany (2021-2030)
  • Table 17: Nuclear Medicine/Radiopharmaceuticals Market Analysis in the UK (2021-2030)
  • Table 18: Nuclear Medicine/Radiopharmaceuticals Market Analysis in Italy (2021-2030)
  • Table 19: Nuclear Medicine/Radiopharmaceuticals Market Analysis in Spain (2021-2030)
  • Table 20: Nuclear Medicine/Radiopharmaceuticals Market Analysis in the Rest of Europe (2021-2030)
  • Table 21: Nuclear Medicine/Radiopharmaceuticals Market Analysis in Asia-Pacific (2021-2030)
  • Table 22: Nuclear Medicine/Radiopharmaceuticals Market Analysis in Asia-Pacific by Country (2021-2030)
  • Table 23: Nuclear Medicine/Radiopharmaceuticals Market Analysis in China (2021-2030)
  • Table 24: Nuclear Medicine/Radiopharmaceuticals Market Analysis in Japan (2021-2030)
  • Table 25: Nuclear Medicine/Radiopharmaceuticals Market Analysis in India (2021-2030)
  • Table 26: Nuclear Medicine/Radiopharmaceuticals Market Analysis in Australia (2021-2030)
  • Table 27: Nuclear Medicine/Radiopharmaceuticals Market Analysis in South Korea (2021-2030)
  • Table 28: Nuclear Medicine/Radiopharmaceuticals Market Analysis in the Rest of Asia-Pacific (2021-2030)
  • Table 29: Nuclear Medicine/Radiopharmaceuticals Market Analysis in the Rest of the World (2021-2030)
  • Table 30: Nuclear Medicine/Radiopharmaceuticals Market Analysis in the Rest of the World by Region (2021-2030)
  • Table 31: Nuclear Medicine/Radiopharmaceuticals Market Analysis in the Middle East (2021-2030)
  • Table 32: Nuclear Medicine/Radiopharmaceuticals Market Analysis in Africa (2021-2030)
  • Table 33: Nuclear Medicine/Radiopharmaceuticals Market Analysis in South America (2021-2030)

List of Figures

  • Figure 1: Competitive Analysis
  • Figure 2: COVID-19 Impact Analysis on Nuclear Medicine/Radiopharmaceuticals Market
  • Figure 3: Nuclear Medicine/Radiopharmaceuticals Market Analysis in Global (2021-2030)
  • Figure 4: Nuclear Medicine/Radiopharmaceuticals Market Analysis in Global by Product Type (2021-2030)
  • Figure 5: Nuclear Medicine/Radiopharmaceuticals Market Analysis in Global by Application (2021-2030)
  • Figure 6: Nuclear Medicine/Radiopharmaceuticals Market Analysis in Global by End-User (2021-2030)
  • Figure 7: Nuclear Medicine/Radiopharmaceuticals Market Analysis in Global by Geography (2021-2030)
  • Figure 8: Nuclear Medicine/Radiopharmaceuticals Market Analysis in North America (2021-2030)
  • Figure 9: Nuclear Medicine/Radiopharmaceuticals Market Analysis in North America by Country (2021-2030)
  • Figure 10: Nuclear Medicine/Radiopharmaceuticals Market Analysis in the US (2021-2030)
  • Figure 11: Nuclear Medicine/Radiopharmaceuticals Market Analysis in Canada (2021-2030)
  • Figure 12: Nuclear Medicine/Radiopharmaceuticals Market Analysis in Mexico (2021-2030)
  • Figure 13: Nuclear Medicine/Radiopharmaceuticals Market Analysis in Europe (2021-2030)
  • Figure 14: Nuclear Medicine/Radiopharmaceuticals Market Analysis in Europe by Country (2021-2030)
  • Figure 15: Nuclear Medicine/Radiopharmaceuticals Market Analysis in France (2021-2030)
  • Figure 16: Nuclear Medicine/Radiopharmaceuticals Market Analysis in Germany (2021-2030)
  • Figure 17: Nuclear Medicine/Radiopharmaceuticals Market Analysis in the UK (2021-2030)
  • Figure 18: Nuclear Medicine/Radiopharmaceuticals Market Analysis in Italy (2021-2030)
  • Figure 19: Nuclear Medicine/Radiopharmaceuticals Market Analysis in Spain (2021-2030)
  • Figure 20: Nuclear Medicine/Radiopharmaceuticals Market Analysis in the Rest of Europe (2021-2030)
  • Figure 21: Nuclear Medicine/Radiopharmaceuticals Market Analysis in Asia-Pacific (2021-2030)
  • Figure 22: Nuclear Medicine/Radiopharmaceuticals Market Analysis in Asia-Pacific by Country (2021-2030)
  • Figure 23: Nuclear Medicine/Radiopharmaceuticals Market Analysis in China (2021-2030)
  • Figure 24: Nuclear Medicine/Radiopharmaceuticals Market Analysis in Japan (2021-2030)
  • Figure 25: Nuclear Medicine/Radiopharmaceuticals Market Analysis in India (2021-2030)
  • Figure 26: Nuclear Medicine/Radiopharmaceuticals Market Analysis in Australia (2021-2030)
  • Figure 27: Nuclear Medicine/Radiopharmaceuticals Market Analysis in South Korea (2021-2030)
  • Figure 28: Nuclear Medicine/Radiopharmaceuticals Market Analysis in the Rest of Asia-Pacific (2021-2030)
  • Figure 29: Nuclear Medicine/Radiopharmaceuticals Market Analysis in the Rest of the World (2021-2030)
  • Figure 30: Nuclear Medicine/Radiopharmaceuticals Market Analysis in the Rest of the World by Region (2021-2030)
  • Figure 31: Nuclear Medicine/Radiopharmaceuticals Market Analysis in the Middle East (2021-2030)
  • Figure 32: Nuclear Medicine/Radiopharmaceuticals Market Analysis in Africa (2021-2030)
  • Figure 33: Nuclear Medicine/Radiopharmaceuticals Market Analysis in South America (2021-2030)
  • Figure 34: Market Drivers
  • Figure 35: Market Barriers
  • Figure 36: Market Opportunities
  • Figure 37: PORTER's Five Force Analysis